Abstract
Gene mutations play a critical role in cancer development and
progression, and their identification offers possibilities for accurate
diagnostics and therapeutic targeting. Finding genes undergoing
mutations is challenging and slow, even in the post-genomic era. A new
approach was recently developed by Noensie and Dietz to prioritize and
focus the search, making use of nonsense-mediated mRNA decay (NMD)
inhibition and microarray analysis (NMD microarrays) in the
identification of transcripts containing nonsense mutations. We combined
NMD microarrays with array-based CGH (comparative genomic
hybridization) in order to identify inactivation of tumor suppressor
genes in cancer. Such a “mutatomics” screening of prostate cancer cell
lines led to the identification of inactivating mutations in the EPHB2
gene. Up to 8% of metastatic uncultured prostate cancers also showed
mutations of this gene whose loss of function may confer loss of tissue
architecture. NMD microarray analysis could turn out to be a powerful
research method to identify novel mutated genes in cancer cell lines,
providing targets that could then be further investigated for their
clinical relevance and therapeutic potential.
Original language | English |
---|---|
Pages (from-to) | 169-173 |
Journal | Cellular Oncology |
Volume | 27 |
Issue number | 3 |
Publication status | Published - 2005 |
MoE publication type | A1 Journal article-refereed |
Keywords
- NMD
- microarray
- mutation
- tumor suppressor gene